Please login to the form below

Not currently logged in

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

First online ADHD treatment test launched in the US

Qbtech brings its QbCheck assessment to market after winning FDA approval

QbCheck Qbtech ADHD online test 

The first FDA-approved online test for attention deficit hyperactivity disorder (ADHD) treatments has been launched in the US.

Developed by Swedish company Qbtech, the QbCheck test aids the assessment and evaluation of treatment interventions in children, adolescents and adults with ADHD.

It measures the three core signs of ADHD - hyperactivity, inattention and impulsivity - and combines a test of sustained attention with a movement analysis based on face tracking technology.

The results are then compared with normative data from groups of people of the same sex and age, with and without ADHD.

Qbtech said the ADHD Total Symptom Score its test uses simplifies the process to identify an individual's likelihood of having ADHD-like symptoms - a feature designed to support improved decision making. 

The privately-owned Swedish company was founded in 2002 with a mission to improve the diagnosis, treatment and follow-up treatment of patients with neuropsychiatric disorders.

It's led by chief executive officer Carl Reuterskiöld, who joined in 2009 from Pfizer, where he spent five years on its Swedish leadership team, including two as director of corporate development and analysis based in Stockholm.

He said: “QbCheck is the first objective online ADHD test in the world to be cleared by the FDA. Being online means that new customer groups including smaller clinics, schools, rural providers and other qualified professionals can provide their patients and clients access to the latest medical technology - a big step to transform the management of ADHD.”

The effectiveness of ADHD treatments are traditionally assessed through a complex - and sometimes costly - combination of clinical interviews and rating scales that have the potential for bias in the feedback provided.

Qbtech's commercial director Tony Doyle, who joined the company in 2010 from Pfizer, where he was head of business effectiveness for its European specialty business unit, said further launches of the product would be forthcoming later this year.

“Even before launch we have seen a fantastic level of interest from hundreds of new professionals keen to use QbCheck to improve their referral process and management of ADHD. An initial launch in the UK in April will be followed by other countries during the summer and autumn.”

QbCheck, which has a CE mark in Europe, is based on the same technology as the company's computer-based QbTest - which also has FDA approval and was launched in 2014, also to evaluate ADHD treatments. QbTest has since been used by approximately 250,000 patients in Europe and the US.

25th April 2016

From: Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
Jet Off with Maloff Protect

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...